PLoS ONE (Sep 2010)

Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease.

  • Tao Ma,
  • Charles A Hoeffer,
  • Estibaliz Capetillo-Zarate,
  • Fangmin Yu,
  • Helen Wong,
  • Michael T Lin,
  • Davide Tampellini,
  • Eric Klann,
  • Robert D Blitzer,
  • Gunnar K Gouras

DOI
https://doi.org/10.1371/journal.pone.0012845
Journal volume & issue
Vol. 5, no. 9

Abstract

Read online

The mammalian target of rapamycin (mTOR) is an evolutionarily conserved Ser/Thr protein kinase that plays a pivotal role in multiple fundamental biological processes, including synaptic plasticity. We explored the relationship between the mTOR pathway and β-amyloid (Aβ)-induced synaptic dysfunction, which is considered to be critical in the pathogenesis of Alzheimer's disease (AD).We provide evidence that inhibition of mTOR signaling correlates with impairment in synaptic plasticity in hippocampal slices from an AD mouse model and in wild-type slices exposed to exogenous Aβ1-42. Importantly, by up-regulating mTOR signaling, glycogen synthase kinase 3 (GSK3) inhibitors rescued LTP in the AD mouse model, and genetic deletion of FK506-binding protein 12 (FKBP12) prevented Aβ-induced impairment in long-term potentiation (LTP). In addition, confocal microscopy demonstrated co-localization of intraneuronal Aβ42 with mTOR.These data support the notion that the mTOR pathway modulates Aβ-related synaptic dysfunction in AD.